reverse-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off white powder | Typical lyophilized form |
| Water solubility | Soluble | May need a small organic co-solvent |
| Purity assessment | Chromatographic peak area | Most certificates report a percentage figure |
| Storage temperature | Minus 20 C or lower | Dry, dark, sealed container |
| Identity check | Electrospray mass spectrometry | Compared against theoretical mass |
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Alcohol (ethanol/ethyl alcohol) – GABAA receptor positive allosteric modulator Alkyl nitrites (poppers) (e.g., amyl nitrite) – nitric oxide donors, vasodilators, muscle relaxants, inhalants Cannabinoids (e.g., THC, cannabis, synthetic cannabinoids) – cannabinoid CB1 receptor agonists Dissociative hallucinogens (e.g., ketamine, methoxetamine, phencyclidine (PCP)) – ionotropic glutamate NMDA receptor antagonists Entactogens (empathogens) (e.g., MDMA (ecstasy), mephedrone, 6-APB, borax combo) – serotonin–norepinephrine–dopamine releasing agents (SNDRAs), other actions γ-Hydroxybutyric acid (GHB; oxybate) and prodrugs (e.g., GBL, 1,4-BD) – GABAB and GHB receptor agonists Phosphodiesterase PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil) Psychostimulants (stimulants) (e.g., amphetamine, methamphetamine, cocaine, mephedrone (4-MMC), metaphedrone (3-MMC), MDPV) – norepinephrine–dopamine releasing agents (NDRAs) and/or norepinephrine–dopamine reuptake inhibitors (NDRIs) Serotonergic psychedelics (e.g., 2C-B, 5-MeO-DiPT, 5-MeO-MiPT) – serotonin 5-HT2A receptor agonists
=== Improving vaccination coverage === Turner has been involved in research into how the structures and organisation of general practice are associated with immunisation coverage in New Zealand. A 2010 paper, co-authored by Turner concluded that while practice immunisation coverage and timeliness did vary widely in New Zealand, "organisational and structural aspects of general practices are key determinants of general practice immunisation delivery". Turner co-authored an Immunisation Advisory Centre (IMAC) study in 2011 that assessed the effectiveness of the cold chain management for delivery of childhood vaccines from national stores to delivery sites in New Zealand. In 2018, IMAC collated a synopsis of strategies used since the 1918 influenza pandemic to deal with unanswered questions about how to manage future pandemics. The data indicated that the burden of the disease in 1918 in New Zealand was inequitably carried by vulnerable populations such as the Maori, Pacific Island and Asian communities. In a related research project, Turner and epidemiologists Nick Wilson and Michael Baker presented data that showed the birth rate for Maori dropped disproportionately after the 2018 pandemic, confirming the importance of pregnant women being vaccinated against seasonal influenza to reduce the rate of stillbirths.
Potential fields of BSG application include ultra-sensitive detectors, high-performance catalytic cells, nanochannels for DNA sequencing and manipulation, high-performance heat sinking surfaces, rechargeable batteries of enhanced performance, nanomechanical resonators, electron multiplication channels in emission Nano-electronic devices, high-capacity sorbents for safe hydrogen storage. Three dimensional bilayer graphene has also been reported.
Picrorhiza kurroa is one of the major income generating non-timber forest products found in the Nepalese Himalayas. It is one of the oldest medicinal plants traded from the Karnali zone. Known as kutki or कुटकी in Nepali, it is a perennial herb and is used as a substitute for Indian gentian (Gentiana kurroo).
He also contributed greatly to the identification of vitamin B complex and was co-author of more than 780 scientific papers on biochemistry and nutrition. Elvehjem commented frequently on nutrition as it affects both scientist and layman. "Vitamins should be obtained from natural foods if possible", he cautioned. "Generally they are cheaper, more palatable, and in better balance with other factors when taken in this form." He acknowledged the value of synthetic vitamins in treating deficiency diseases, but warned that their use should be temporary. Elvehjem's first graduate student (in 1931) was noted nutritionist Fredrick John Stare (1910–2002) who later founded and chaired the department of nutrition at the Harvard School of Public Health, where he served until 1976. Elvehjem met his wife Constance W. Elvehjem when she was an undergraduate at UW Madison. She died in 1999 at the age of 94 after many years supporting the museum and the Madison community. Elvehjem was stricken with a heart attack at his desk on the morning of July 27, 1962, at the age of sixty-one and died within the hour.
Sources: en.wikipedia.org
=== Diagnostic biomarkers === Guidelines outlining requirements for inclusion of soluble biomarkers in osteoarthritis clinical trials were published in 2015, but there are no validated biomarkers used clinically to detect osteoarthritis, as of 2021. A 2015 systematic review of biomarkers for osteoarthritis, looking for molecules that could be used for risk assessments, found 37 different biochemical markers of bone and cartilage turnover in 25 publications. The strongest evidence was for urinary C-terminal telopeptide of type II collagen (uCTX-II) as a prognostic marker for knee osteoarthritis progression, and serum cartilage oligomeric matrix protein (COMP) levels as a prognostic marker for incidence of both knee and hip osteoarthritis. A review of biomarkers in hip osteoarthritis also found associations with uCTX-II. Procollagen type II C-terminal propeptide (PIICP) levels reflect type II collagen synthesis in body and within joint fluid PIICP levels can be used as a prognostic marker for early osteoarthritis.
=== History === Cornish-Bowden, Athel (1997). New Beer in an Old Bottle. Eduard Buchner and the Growth of Biochemical Knowledge. Valencia: Universitat de Valencia. ISBN 978-84-370-3328-0. Archived from the original on 13 December 2010. Retrieved 8 December 2007., A history of early enzymology. Williams, Henry Smith (1904). Modern Development of the Chemical and Biological Sciences. A History of Science: in Five Volumes. Vol. IV. New York: Harper and Brothers. Archived from the original on 9 May 2012. Retrieved 8 December 2007., a textbook from the 19th century.
=== Economics === Concerns have been raised about the growing use of modafinil as a "smart drug" or cognitive enhancer among healthy individuals who use it with the aim to improve concentration and memory. In 2003, modafinil sales rose sharply amid concern that it was being used as a stimulant by people seeking an extra edge. The cost of modafinil has decreased substantially since generic versions became available in the US in 2012; retail prices for generic modafinil (30 tablets of 200 mg) range from approximately $20 to $45 with discount programs, compared to over $120 per month for brand-name Provigil in 2004. Global sales figures for modafinil have not been publicly disclosed. Modafinil sold under the brand name Provigil accounted for over 40% of Cephalon's global turnover for several years, according to data published in 2020.
=== 26 March === The SAF retook Khartoum International Airport and the Manshiya Bridge over the Blue Nile in Khartoum. It also retook the Tiba al-Hassanab camp in Jabal Aulia, which is described as the RSF's last stronghold in Khartoum and its main base in central Sudan. Al-Burhan visited the presidential palace in Khartoum and announced the liberation of the city, proclaiming that "Khartoum is free".
An alginate dressing is a natural wound dressing derived from carbohydrate sources released by clinical bacterial species, in the same manner as biofilm formation. These types of dressings are best used on wounds that have a large amount of exudate. They may be used on full-thickness burns, surgical wounds, split-thickness graft donor sites, Mohs surgery defects, refractory decubiti, and chronic ulcers. They can also be applied onto dry wounds after normal saline is first applied to the site of application. Alginate dressings are produced from the calcium and sodium salts of alginic acid, a polysaccharide comprising mannuronic and guluronic acid units. Alginate is initially extracted from the cell wall of brown seaweeds. Alginate dressings can be in the form of freeze-dried, porous (foam) sheets or flexible fibres. Flexible fibres are used to treat cavity wounds. The alginate will form a gel in contact with the exudates of the wound and give it a strong absorbent power.
Sources: en.wikipedia.org
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.
Yes. Degradation proceeds faster once the powder is dissolved, especially at room temperature or after multiple freeze and thaw cycles. Working solutions are often aliquoted to avoid repeated handling. Lyophilized powder held cold and dry retains its properties far longer.
Truncated sequences, oxidized residues and aggregated forms can all elute near the main peak. Reversed phase chromatography resolves many of these species, so the number of peaks is a useful indicator of synthesis quality. A single peak does not by itself prove correct sequence, which is why mass confirmation is paired with it.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.